查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗体药物偶联物(ADC)合同製造市场规模,份额和趋势分析报告：按接头（裂解,非裂解）,疾病（骨髓瘤,淋巴瘤,乳腺癌）,地区,细分市场预测2023-2030
市场调查报告书
商品编码
1171048

抗体药物偶联物(ADC)合同製造市场规模,份额和趋势分析报告：按接头（裂解,非裂解）,疾病（骨髓瘤,淋巴瘤,乳腺癌）,地区,细分市场预测2023-2030

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

抗体偶联药物 (ADC) 合同製造市场的增长和趋势

Grand View Research, Inc. 的一份新报告显示，到 2030 年，全球抗体药物偶联物 (ADC) 合同製造市场规模将达到 257.9 亿美元，预测期内的复合年增长率为 12.9% 亿美元。 抗体药物偶联物 (ADC) 的复杂性推动了行业增长，这有助于合同製造的需求、对抗体疗法的研究增加以及癌症患病率上升。 在大流行期间，针对癌症的临床试验曾短暂停止。 但由于病情严重，临床试验又重新开始。 根据 IQVIA Oncology Trends Report 2022，癌症临床试验的数量正在增加。

根据 IQVIA 的一份报告，从 2016 年到 2021 年，肿瘤学临床试验增加了 56%。 由于全球癌症患病率的增加，预计临床试验的数量将进一步增加。 预计这将支持大流行后的行业增长，因为它支持 ADC 开发和製造活动。 抗体-药物偶联物在治疗癌症方面非常有效，因为它们只针对癌细胞，而不会影响体内的健康细胞。 因此，一些生物製药公司已获得大量资金用于 ADC 相关研究。

例如，2022 年 10 月，Mablink Bioscience 筹集了 3100 万美元的 A 系列资金，用于建立抗体-药物偶联物管线。 因此，预计未来几年对 ADC 研发的大量投资将提高其可用性，从而支持对 ADC 合同製造的需求。 2021年9月，美国FDA加速批准ADC tisotumab vedotin-tftv用于治疗晚期、復发或转移性宫颈癌或化疗后的成年患者。 在接下来的几年里，此类批准预计将推动对 ADC 合同製造服务的需求。

抗体偶联药物 (ADC) 合同製造市场报告要点

按疾病分类，淋巴瘤部分预计在预测期内以最快的复合年增长率增长

大量正在开发的淋巴瘤 ADC 以及针对淋巴瘤的 ADC 相关研究的合作将在预测期内支持该细分市场的增长

基于链接器，可切割链接器部分占 2022 年总收入的最大份额

在 ADC 中广泛使用可切割接头技术以及管道中大量基于可切割接头的产品正在推动细分市场的增长

2022年，亚太地区主导全球产业，收入占比最大

这是因为与发达国家相比，新兴市场的研发活动有了很大改善，而且该地区的製造成本较低

内容

第1章调查方法及范围

  • 市场细分和范围
    • 语气
    • 链接器
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析（模型 1）
      • 方法 1：商品流方法
  • 二级信息列表
  • 主要信息列表
  • 目的

第 2 章执行摘要

  • 市场前景

第 3 章抗体药物偶联物 (ADC) 合同製造市场变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
    • 相关/子公司市场前景
  • 市场动态
    • 市场驱动因素分析
      • 癌症发病率增加
      • 製造 ADC 的高成本以及与製造相关的挑战推动了对合同製造的需求
      • 增加 ADC 研发活动
    • 市场製约因素分析
      • 外包时的质量问题
      • 主要生物製药公司选择的有限外包
  • 抗体偶联药物合同製造市场分析工具
    • 波特的五力分析
    • PESTLE 分析
    • 对主要交易和战略联盟的分析
      • 併购
      • 分机
      • 合同和合作
      • 产品和服务发布
  • COVID-19 的影响和改革战略

第 4 章抗体药物偶联物 (ADC) 合同製造市场：状态估计和趋势分析

  • 定义和范围
  • 抗体药物偶联物 (ADC) 合同製造市场份额，2022 年和 2030 年
  • 骨髓瘤
  • 淋巴瘤
  • 乳腺癌
  • 其他

第 5 章抗体药物偶联物 (ADC) 合同製造市场：接头估计和趋势分析

  • 定义和范围
  • 抗体药物偶联物 (ADC) 合同製造市场份额，2022 年和 2030 年
  • 可切割接头
  • 不可切割的链接器

第 6 章抗体药物偶联物 (ADC) 合同製造市场：区域估计和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 多边环境协定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第7章竞争分析

  • 主要市场进入者的近期发展和影响分析
  • 公司/竞争对手分类（主要创新者、市场领导者、初创企业）
  • 参与者分类

第8章竞争格局

  • 公司简介
    • Recipharm AB
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 三星生物製品
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 龙沙
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • Piramal Group (Piramal Pharma Solutions)
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 英镑
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 赛多利斯公司
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 康泰伦特公司
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 无锡生物
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • AbbVie, Inc.（艾伯维合同製造）
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
    • 默克公司
      • 公司概况
      • 财务业绩
      • 服务基准
      • 战略举措
Product Code: GVR-4-68039-623-5

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 25.79 billion by 2030, registering a CAGR of 12.9% over the forecast period, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

  • By condition, the lymphoma segment is expected to grow at the fastest CAGR over the forecast period
  • A significant number of ADCs under development for lymphoma and collaborations for ADC-related research for lymphoma are supporting the growth of the segment over the forecast period
  • Based on the linker, the cleavable linker segment accounted for the maximum share of the overall revenue in 2022
  • Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based products in the pipeline are the factors responsible for the segment growth
  • Asia Pacific dominated the global industry in 2022 and accounted for the maximum revenue share
  • This is due to the robust improvements in R&D activities in emerging markets and low-cost manufacturing in the region as compared to that of developed countries

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Condition
    • 1.1.2. Linker
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Antibody Drug Conjugates Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer
      • 3.2.1.2. High cost of manufacturing ADC and challenges associated with manufacturing contributing to the demand for contract manufacturing
      • 3.2.1.3. Increasing R&D activities on ADCs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Quality issues while outsourcing
      • 3.2.2.2. Limited outsourcing opted by big biopharma Companies
  • 3.3. Antibody Drug Conjugates Contract Manufacturing Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Major Deals & Strategic Alliances Analysis
      • 3.3.3.1. Mergers and acquisition
      • 3.3.3.2. Expansions
      • 3.3.3.3. Agreements and collaborations
      • 3.3.3.4. Product and service launches
  • 3.4. Covid-19 Impact and Reformation Strategy

Chapter 4. Antibody Drug Conjugates Contract Manufacturing Market: Condition Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
  • 4.3. Myeloma
    • 4.3.1. Myeloma market estimates and forecast 2018 to 2030 (USD Million)
  • 4.4. Lymphoma
    • 4.4.1. Lymphoma market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Breast Cancer
    • 4.5.1. Breast Cancer market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates Contract Manufacturing Market: Linker Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
  • 5.3. Cleavable linker
    • 5.3.1. Cleavable linker market estimates and forecast 2018 to 2030 (USD Million)
  • 5.4. Non-cleavable linker
    • 5.4.1. Non-cleavable linker market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 6.1. Regional market share analysis, 2022 & 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. U.S. market estimates and forecast, 2018 - 2030
    • 6.2.2. Canada
      • 6.2.2.1. Canada market estimates and forecast, 2018 - 2030
  • 6.3. Europe
    • 6.3.1. U.K.
      • 6.3.1.1. U.K. market estimates and forecast, 2018 - 2030
    • 6.3.2. Germany
      • 6.3.2.1. Germany market estimates and forecast, 2018 - 2030
    • 6.3.3. France
      • 6.3.3.1. France market estimates and forecast, 2018 - 2030
    • 6.3.4. Italy
      • 6.3.4.1. Italy market estimates and forecast, 2018 - 2030
    • 6.3.5. Spain
      • 6.3.5.1. Spain market estimates and forecast, 2018 - 2030
    • 6.3.6. Denmark
      • 6.3.6.1. Denmark market estimates and forecast, 2018 - 2030
    • 6.3.7. Sweden
      • 6.3.7.1. Sweden market estimates and forecast, 2018 - 2030
    • 6.3.8. Norway
      • 6.3.8.1. Norway market estimates and forecast, 2018 - 2030
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Japan market estimates and forecast, 2018 - 2030
    • 6.4.2. China
      • 6.4.2.1. China market estimates and forecast, 2018 - 2030
    • 6.4.3. India
      • 6.4.3.1. India market estimates and forecast, 2018 - 2030
    • 6.4.4. Australia
      • 6.4.4.1. Australia market estimates and forecast, 2018 - 2030
    • 6.4.5. Thailand
      • 6.4.5.1. Thailand market estimates and forecast, 2018 - 2030
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea market estimates and forecast, 2018 - 2030
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Brazil market estimates and forecast, 2018 - 2030
    • 6.5.2. Mexico
      • 6.5.2.1. Mexico market estimates and forecast, 2018 - 2030
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina market estimates and forecast, 2018 - 2030
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. South Africa market estimates and forecast, 2018 - 2030
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030
    • 6.6.3. UAE
      • 6.6.3.1. UAE market estimates and forecast, 2018 - 2030
    • 6.6.4. Kuwait
      • 6.6.4.1. Kuwait market estimates and forecast, 2018 - 2030

Chapter 7. Competitive Analysis

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participant
  • 7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 7.3. Participant Categorization

Chapter 8. Competitive Landscape

  • 8.1. Company Profiles
    • 8.1.1. Recipharm AB
      • 8.1.1.1. Company overview
      • 8.1.1.2. Financial performance
      • 8.1.1.3. Service benchmarking
      • 8.1.1.4. Strategic initiatives
    • 8.1.2. Samsung Biologics
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Service benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. Lonza
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Service benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Piramal Group (Piramal Pharma Solutions)
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Service benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. Sterling
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Service benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Sartorius AG
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Service benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. Catalent, Inc
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Service benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. Wuxi Biologics
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Service benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Service benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Merck KGaA
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Service benchmarking
      • 8.1.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Antibody drug conjugates contract manufacturing market snapshot (2022)
  • Fig. 11 Antibody drug conjugates contract manufacturing market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Antibody drug conjugates contract manufacturing market condition outlook: Segment dashboard
  • Fig. 18 Antibody drug conjugates contract manufacturing market: Condition movement analysis
  • Fig. 19 Myeloma market (USD Million)
  • Fig. 20 Lymphoma market (USD Million)
  • Fig. 21 Breast Cancer market (USD Million)
  • Fig. 22 Others market (USD Million)
  • Fig. 23 Antibody drug conjugates contract manufacturing market linker outlook: Segment dashboard
  • Fig. 24 Antibody drug conjugates contract manufacturing market: Linker movement analysis
  • Fig. 25 Cleavable Linker market (USD Million)
  • Fig. 26 Non-Clevable Linker market (USD Million)
  • Fig. 27 Regional market: Key takeaways
  • Fig. 28 Regional outlook, 2022 & 2030
  • Fig. 29 North America market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Market, , 2018 -2030 (USD Million)
  • Fig. 32 Europe Market, , 2018 -2030 (USD Million)
  • Fig. 33 U.K. Market, , 2018 -2030 (USD Million)
  • Fig. 34 Germany Market, , 2018 -2030 (USD Million)
  • Fig. 35 France Market, , 2018 -2030 (USD Million)
  • Fig. 36 Italy Market, 2018 -2030 (USD Million)
  • Fig. 37 SpainMarket, 2018 -2030 (USD Million)
  • Fig. 38 Denmark Market, 2018 -2030 (USD Million)
  • Fig. 39 SwedenMarket, 2018 -2030 (USD Million)
  • Fig. 40 Norway Market, By Service, 2018 -2030 (USD Million)
  • Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 42 China market, 2018 - 2030 (USD Million)
  • Fig. 43 India market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait market, 2018 - 2030 (USD Million)